Coya yesterday reported their low dose Il-2 phase
Post# of 148110
(Total Views: 384)
Posted On: 10/30/2024 8:52:30 AM
Quote:
Coya yesterday reported their low dose Il-2 phase 2 Alzheimer's results. Seems mixed results with lower dosage of treatment every four weeks providing a slowing in cognitive decline. Meanwhile, higher dosage of treatment every two weeks appeared no better than placebo.
No surprise there. Lower amounts of IL-2 would increase T-regulatory cells decreasing inflammation a bit. Higher levels of IL-2 increase inflammatory cytokines and cell killing macrophages which would negatively affect Alzheimer's.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼